Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in sickle cell disease.

Long-term BCL11A silencing via shmiR vector in Sickle Cell Disease shows durable HbF induction and sustained clinical benefits over 48 months.

• Why it matters: Effective, lasting therapies for SCD are needed to reduce painful vaso-occlusive episodes and prevent organ damage, addressing a significant treatment gap.
• What they did: Eleven patients underwent HSC collection and transduction with a lentivirus vector targeting BCL11A, achieving 93.1% transduction efficiency and successful engraftment in 10 patients, with follow-up averaging 58 months.
• The result: Nine patients maintained high levels of fetal hemoglobin and experienced durable reduction in pain episodes, demonstrating the vector’s safety and long-term efficacy, supporting further clinical trials.